Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ADTX 
Aditxt Inc. (ADTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: ADTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $61
1 Year Target Price $61
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49M USD | Price to earnings Ratio - | 1Y Target Price 61 |
Price to earnings Ratio - | 1Y Target Price 61 | ||
Volume (30-day avg) 1 | Beta 1.32 | 52 Weeks Range 0.29 - 225.00 | Updated Date 10/23/2025 |
52 Weeks Range 0.29 - 225.00 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2942.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -612788.4% |
Management Effectiveness
Return on Assets (TTM) -45.26% | Return on Equity (TTM) -282.21% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 8940971 | Price to Sales(TTM) 123.8 |
Enterprise Value 8940971 | Price to Sales(TTM) 123.8 | ||
Enterprise Value to Revenue 741.93 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 4976555 | Shares Floating 4976555 |
Shares Outstanding 4976555 | Shares Floating 4976555 | ||
Percent Insiders - | Percent Institutions 0.79 |
Upturn AI SWOT
Aditxt Inc.
Company Overview
History and Background
Aditxt, Inc. (ADTX) was incorporated in Nevada in 2017. It focuses on developing and commercializing technologies focused on improving the health of the immune system. It has evolved through acquisitions and internal development to pursue its mission.
Core Business Areas
- AditxtScore: A diagnostic test designed to provide a comprehensive assessment of an individual's immune system function.
- AditxtReprogramming: Development of technologies aimed at modulating and reprogramming the immune system to treat or prevent diseases.
- AditxtRx: Efforts to create personalized therapeutics based on an individual's immune profile and needs.
Leadership and Structure
Amro Albanna serves as the Chief Executive Officer. The organizational structure consists of departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- AditxtScore: AditxtScore, its lead product, is an immune monitoring platform. Market share data is not readily available as it is still early in its market penetration phase. Competitors include companies offering broad immune assessment or diagnostics in organ transplantation and autoimmunity. Specific competitors will depend on the clinical use case and geographic market.
Market Dynamics
Industry Overview
The industry is biotechnology, specifically focused on immune system monitoring and modulation. It is characterized by high growth potential, innovation, and significant regulatory hurdles. The industry relies on personalized medicine, immune diagnostics, and therapeutics.
Positioning
Aditxt is positioned as an innovator in the emerging field of immune monitoring and reprogramming. Its competitive advantage lies in its unique technology platform.
Total Addressable Market (TAM)
The TAM for immune monitoring and therapeutics is estimated to be in the billions of dollars globally. Aditxt is positioned to capture a share of this market through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative Technology Platform
- Experienced Leadership Team
- Focus on Personalized Medicine
- Intellectual Property Portfolio
Weaknesses
- Limited Revenue Generation
- Dependence on Future Funding
- Small Company Size
- Regulatory Risks
Opportunities
- Strategic Partnerships
- Expansion into New Markets
- FDA Approvals
- Growing Awareness of Immune Health
Threats
- Competition from Larger Companies
- Regulatory Changes
- Clinical Trial Failures
- Economic Downturn
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BMY
- GILD
Competitive Landscape
Aditxt faces significant competition from larger, more established pharmaceutical companies. Its advantage lies in its niche focus and innovative technology, but it must overcome challenges related to funding and regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development, not revenue generation.
Future Projections: Future growth projections depend on successful clinical trials, regulatory approvals, and commercialization of its products.
Recent Initiatives: Recent initiatives include advancing clinical trials and seeking strategic partnerships.
Summary
Aditxt Inc. is a development-stage biotechnology company with a focus on immune system monitoring and modulation. The company has innovative technology, but is financially weak. Success depends on future clinical trials, regulatory approvals, and market adoption of its products. The company is a high-risk, high-reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports (where available)
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The accuracy of the data is not guaranteed. Market share data is estimated based on available sources and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aditxt Inc.
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2020-06-30 | Co-Founder, Chairman, CEO & President Mr. Amro A. Albanna | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.aditxt.com |
Full time employees 26 | Website https://www.aditxt.com | ||
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.